The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
Clinical Breast Cancer · 2023
DOI: 10.1016/j.clbc.2023.05.015 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Breast Cancer, 2023. Verfasst von Yakup Ergun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Batman World Hospital, Batman, Turkey. Electronic address: dr.yakupergun@gmail.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
This meta-analysis conducted a comprehensive analysis of research investigating the correlation between HER2 expression levels and treatment outcomes in early-stage triple-negative breast cancer (TNBC) patients. We systematically searched major databases for studies published up to January 01, 2023. The data from various studies examined the relationship between HER2-zero and HER2-low tumors in terms of pathological complete response (pCR) rates, disease-free survival (DFS), and overall survival (OS) outcomes. The odds ratio (OR) and 95% confidence interval (CI) by the number of events were calculated using the Mantel-Haenszel method to analyze pCR. The hazard ratio and 95% CI were calculated using the inverse variance method for DFS and OS. In all comparisons, I2 was 0% and no heterogeneity was detected. A total of 12 retrospective studies involving 4094 patients were included. Thirty-six percent of the patients were in the HER2-low group. All 12 studies were included in the pooled analysis for pCR, and there was no difference between HER2-zero and HER2-low (40% vs. 38%, respectively; pooled OR:1.01 95% CI 0.88-1.16; I2: 0%). Four studies were included in the pooled analysis for DFS and 3 in the OS analysis. DFS and OS were significantly better in the HER2-low group (pooled hazard ratio: 0.67 for DFS, 0.64 for OS). There was no difference between HER2-low and HER2-zero in terms of pCR in early-stage TNBC. However, HER2-low was found to be associated with prolonged DFS and OS. PROSPERO REGISTRATION NUMBER: CRD42023391002.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Batman World Hospital, Batman, Turkey. Electronic address: dr.yakupergun@gmail.com.
- Department of Medical Oncology, Binali Yıldırım University Mengücek Gazi Training and Research Hospital, Erzincan, Turkey.
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
- Department of Medical Oncology, VM Medical Park Maltepe Hospital, Istanbul, Turkey.
- Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
Zitieren
APA
Ergun, Y., Akagunduz, B., Karacin, C., Turker, S., & Ucar, G. (2023). The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.05.015
Vancouver
Ergun Y, Akagunduz B, Karacin C, Turker S, Ucar G. The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis. Clinical Breast Cancer. 2023. doi:10.1016/j.clbc.2023.05.015
BibTeX
@article{Ergun2023,
author = {Ergun, Yakup and Akagunduz, Baran and Karacin, Cengiz and Turker, Sema and Ucar, Gokhan},
title = {The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis},
journal = {Clinical Breast Cancer},
year = {2023},
doi = {10.1016/j.clbc.2023.05.015}
}
EUVIMED